REG - BioPharma Credit PLC - Notice of Half Year Results

Biopharma CreditAnnouncement

31/08/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230831:nRSe8498Ka&default-theme=true

RNS Number : 8498K  BioPharma Credit PLC  31 August 2023

31 August 2023

BIOPHARMA CREDIT PLC

(the "Company")

NOTICE OF HALF YEAR RESULTS

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor,
will announce its Half Year Results for the period ending 30 June 2023 on
Wednesday 27 September 2023.

A management presentation will be delivered at 14.00 BST through a webcast
facility. To register to attend or request details, RSVP
to biopharmacredit@buchanan.uk.com.

-Ends-

Enquiries

BioPharma Credit PLC

via Link Company Matters Limited

Company Secretary

+44 (0)333 300 1950

Buchanan

+44 (0)20 7466 5000

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

biopharmacredit@buchanan.uk.com

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from
the life sciences industry and joined the LSE on 27 March 2017. The Company
seeks to provide long-term shareholder returns, principally in the form of
sustainable income distributions from exposure to the life sciences industry.
The Company seeks to achieve this objective primarily through investments in
debt assets secured by royalties or other cash flows derived from the sales of
approved life sciences products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORKZGFRDGLGFZM